Clinical trials: Tauopathies
Alzheimer Disease
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
- Trial name
- NCT03367403
- Testing
- Donanemab, LY3202626
- Where
- 61 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables
This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05159557
- Testing
- In-Home Technology System, Limited In-Home Technology
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers.
- Trial name
- NCT01126099
- Testing
- Prazosin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Alzheimer's Disease
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind…
- Trial name
- NCT02586909
- Testing
- RVT-101 35 mg tablets
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,099 people
- Sponsor
- Axovant Sciences Ltd.
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia…
- Trial name
- NCT02972658
- Testing
- Lanabecestat
- Where
- 133 sites in United States, Australia and 12 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.
- Trial name
- ALPO (NCT01324518)
- Testing
- ORM-12741
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Orion Corporation, Orion Pharma
Alzheimer's Disease
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal…
- Trial name
- NCT01399125
- Testing
- Rivastigmine Patch, Rivastigmine Capsules
- Where
- 16 sites in China
- Volunteers
- 501 people
- Sponsor
- Novartis Pharmaceuticals
Low Education, Cognition
MINDSpeed Food and Brain Training RCT
The purpose of this study is to learn how foods high in polyphenols and brain training exercises affect older adults' cognitive performance
- Conditions
- Low Education, Cognition, Cognitive Training, Polyphenols
- Trial name
- MINDSpeed (NCT03419052)
- Testing
- Speed of processing training, MIND foods, Cognitive training control
- Where
- United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer's Disease
Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease
This study is designed to assess the safety and toxicity/adverse events associated with the use of low dose fractionated whole brain irradiation in those patients who have been diagnosed with probable Alzheimer's disease…
- Trial name
- NCT02359864
- Testing
- 5 daily fractions of 2 Gy, 10 daily fractions of 2 Gy
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corewell Health East
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Trial name
- ADVANCE-2 (NCT05557409)
- Testing
- AXS-05
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 408 people
- Sponsor
- Axsome Therapeutics, Inc.
Alzheimer Disease
Detecting an Early Response to Donepezil With Measures of Visual Attention
Acetylcholinesterase inhibitors (AChE-I) comprise a class of drugs used to treat Alzheimer's disease (AD), but controversy about their usefulness remains.
- Trial name
- NCT03073876
- Testing
- Donepezil Hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Alzheimer's Disease
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky protein in the brain…
- Trial name
- IDENTITY-2 (NCT00762411)
- Testing
- LY450139
- Where
- 91 sites in United States, Brazil and 16 more
- Volunteers
- 1,111 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD)…
- Trial name
- NCT03823404
- Testing
- COR388 capsule
- Where
- 93 sites in United States, France and 4 more
- Volunteers
- 643 people
- Sponsor
- Cortexyme Inc.
Alzheimer Disease
Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease
In the current study, we will examine how two types of concentration meditation practices affect plasma biomarkers of Alzheimer's Disease (AD).
- Trial name
- NCT06210035
- Testing
- Belly-focus meditation, Belly-focus meditation with slow breathing
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer's Disease
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 78 weeks in the treatment of…
- Trial name
- EPOCH (NCT01739348)
- Testing
- Verubecestat (Part I and Part II), Verubecestat (Part II)
- Volunteers
- 2,211 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease.
- Trial name
- NCT03289143
- Testing
- Semorinemab, [18F]GTP1
- Where
- 133 sites in United States, Australia and 11 more
- Volunteers
- 457 people
- Sponsor
- Genentech, Inc.
Dementia, Alzheimer Disease
Using Technology to Support Care Partners for Persons With Alzheimer's Disease: Tele-STELLA
The purpose of this study is to test a revised psychoeducational intervention to help Care Partners for family members with dementia understand and reduce the distressing behaviors that come with progressive dementia.
- Conditions
- Dementia, Alzheimer Disease, Caregiver Burnout, Family Members
- Trial name
- Tele-STELLA (NCT04627662)
- Testing
- Tele-STELLA
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Oregon Health and Science University
Alzheimer's Disease
Trial of Rifaximin in Probable Alzheimer's Disease
This study aims to improve cognition and function in patients with Alzheimer's Disease (AD) by administering the oral antibiotic, Rifaximin.
- Trial name
- NCT03856359
- Testing
- Rifaximin 550 milligrams (MG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Alzheimer Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 in participants in the early Alzheimer's disease (AD [progressive brain disease that slowly destroys memory and thinking skills, and…
- Trial name
- NCT02406027
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, JNJ-54861911, 5 mg
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC